Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen in Duchenne Muscular Dystrophy
NCT02835079Phase 1Completed
- Sponsor
- Hadassah Medical Organization
- Start
- Nov 2016
- Primary completion
- Nov 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of tamoxifen in Duchenne muscular dystrophy (DMD), sponsored by Hadassah Medical Organization. Primary endpoint: 6-minute walk distance at 36 months. Started Nov 2016; status: completed.
02
Drugs
tamoxifen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02835079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02835079.